07:00 , Aug 20, 2012 |  BC Week In Review  |  Clinical News

Bactramin regulatory update

Japan's Ministry of Health Labor and Welfare approved an application to expand the label for Bactramin sulfamethoxazole/trimethoprim to include the treatment and prevention of Pneumocystis pneumonia infection. The synthetic antibacterial agent is approved in Japan...
08:00 , Feb 20, 2012 |  BC Week In Review  |  Clinical News

Bactramin regulatory update

Chugai submitted a regulatory application in Japan to expand the label of antibiotic Bactramin sulfamethoxazole/trimethoprim to include the prevention of Pneumocystis pneumonia infection. The synthetic antibacterial agent is approved in Japan to treat pneumonia, secondary...
07:00 , May 25, 2009 |  BC Week In Review  |  Company News

moksha8 Inc., Roche sales and marketing update

Roche granted moksha8 an exclusive license to commercialize 16 marketed drugs in Mexico. The portfolio includes Rivotril clonazepam to treat anxiety, epilepsy and panic disorders, and antibiotics Rocephin ceftriaxone and Bactrim sulfamethoxazole/trimethoprim. moksha8 said...
07:00 , Apr 28, 2008 |  BioCentury  |  Emerging Company Profile

moksha8: Racing into emerging markets

Despite attractive growth in emerging markets such as Brazil, Asia, Eastern Europe and the Middle East, many pharma companies and large biotechs lack the wherewithal or incentive to market their own drugs in these regions,...
07:00 , Apr 21, 2008 |  BC Week In Review  |  Company News

moksha8, Pfizer, Roche deal

moksha8 announced deals with Roche and Pfizer to commercialize 22 marketed drugs in high-growth emerging markets including Brazil, where moksha8 also opened its Latin American headquarters. moksha8's initial portfolio includes Zoloft sertraline to treat...
01:10 , Apr 17, 2008 |  BC Extra  |  Company News

moksha8 unveils agreements with Roche, Pfizer

moksha8 announced deals with Roche (SWX:ROG) and Pfizer (NYSE:PFE) on Wednesday to commercialize 22 marketed drugs in high-growth emerging markets including Brazil, where moksha8 also opened its Latin American headquarters. moksha8's initial portfolio includes Zoloft...
08:00 , Oct 30, 2006 |  BioCentury  |  Regulation

On the market

On the market Product Class Amoxil amoxicillin (GlaxoSmithKline) Beta-lactam Augmentin amoxicillin/clavulanate (GlaxoSmithKline) Beta-lactam Omnicef cefdinir (Abbott) Beta-lactam Ceftin cefuroxime (GlaxoSmithKline) Beta-lactam Cefzil cefprozil (Bristol-Myers) Beta-lactam Vantin cefpodoxime (Pfizer) Beta-lactam Avelox moxifloxacin (Bayer) Fluoroquinolone Cipro ciprofloxacin...
07:00 , Sep 25, 1995 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

U.S. Bioscience Inc. (UBS) Business: Cancer Merrill Lynch analyst Richard Vietor said he expects the West Conshohocken, Penn., company's Ethyol to receive FDA marketing approval by year end, with a label to prevent cumulative...